0001104659-25-024062.txt : 20250314 0001104659-25-024062.hdr.sgml : 20250314 20250314182046 ACCESSION NUMBER: 0001104659-25-024062 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20250312 FILED AS OF DATE: 20250314 DATE AS OF CHANGE: 20250314 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Ali Asif CENTRAL INDEX KEY: 0001921163 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37852 FILM NUMBER: 25741676 MAIL ADDRESS: STREET 1: 7707 GATEWAY BLVD., SUITE 140 CITY: NEWARK STATE: CA ZIP: 94560 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Protagonist Therapeutics, Inc CENTRAL INDEX KEY: 0001377121 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 980505495 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 7707 GATEWAY BLVD., SUITE 140 CITY: NEWARK STATE: CA ZIP: 94560-1160 BUSINESS PHONE: (510) 474-0170 MAIL ADDRESS: STREET 1: 7707 GATEWAY BLVD., SUITE 140 CITY: NEWARK STATE: CA ZIP: 94560-1160 FORMER COMPANY: FORMER CONFORMED NAME: Protagonist Therapeutics Inc DATE OF NAME CHANGE: 20130605 FORMER COMPANY: FORMER CONFORMED NAME: Protagonist Inc DATE OF NAME CHANGE: 20061002 4 1 tm259281-1_4seq1.xml OWNERSHIP DOCUMENT X0508 4 2025-03-12 0 0001377121 Protagonist Therapeutics, Inc PTGX 0001921163 Ali Asif C/O PROTAGONIST THERAPEUTICS, INC. 7707 GATEWAY BLVD., SUITE 140 NEWARK CA 94560-1160 0 1 0 0 Chief Financial Officer 0 Common Stock 2025-03-12 4 M 0 15203 12.17 A 78024 D Common Stock 2025-03-12 4 M 0 9700 19.19 A 87724 D Common Stock 2025-03-12 4 S 0 24903 58.73 D 62821 D Stock Option (right to buy) 12.17 2025-03-12 4 M 0 15203 0.00 D 2033-01-15 Common Stock 15203 30547 D Stock Option (right to buy) 19.19 2025-03-12 4 M 0 9700 0.00 D 2032-04-18 Common Stock 9700 66800 D The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $58.12 to $59.235. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. The stock option was granted to the Reporting Person on January 16, 2023 and vests in 48 equal monthly installments following the date of grant, subject to the Reporting Person's continued service to the Issuer. The stock option was granted to the Reporting Person on April 18, 2022, one quarter vested on April 18, 2023 and the remaining three quarters vest in equal monthly installments through April 18, 2026, subject to the Reporting Person's continued service to the Issuer. /s/ Matthew Gosling, Attorney-in-Fact for Asif Ali 2025-03-14